MCID: ALK015
MIFTS: 39

Alk-Positive Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Positive Anaplastic Large Cell Lymphoma:

Name: Alk-Positive Anaplastic Large Cell Lymphoma 58
Anaplastic Large Cell Lymphoma, Alk Negative 70
Anaplastic Large Cell Lymphoma, Alk-Positive 70
Alk+ Anaplastic Large Cell Lymphoma 58
Alk+ Alcl 58

Characteristics:

Orphanet epidemiological data:

58
alk-positive anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C84.6
Orphanet 58 ORPHA300895
UMLS 70 C1332078 C1332079

Summaries for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Positive Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk negative, is related to peripheral t-cell lymphoma and anaplastic large cell lymphoma. An important gene associated with Alk-Positive Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Carmustine and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and myeloid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Alk-Positive Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Related Disease Score Top Affiliating Genes
1 peripheral t-cell lymphoma 31.6 TNFRSF8 STAT3 JAK3 ALK
2 anaplastic large cell lymphoma 30.9 TNFRSF8 STAT3 NPM1 JAK3 ALK
3 lymphoma 30.9 TNFRSF8 NPM1 BCL2L1 ALK
4 bone lymphoma 30.6 TNFRSF8 ALK
5 primary cutaneous anaplastic large cell lymphoma 30.6 NPM1 ALK
6 lymphoma, hodgkin, classic 30.5 TNFRSF8 BCL2L1 ALK
7 reticulosarcoma 30.5 TNFRSF8 NPM1 ALK
8 breast lymphoma 30.3 TNFRSF8 ALK
9 pericardial effusion 30.3 TNFRSF8 ALK
10 inflammatory myofibroblastic tumor 30.2 NPM1 ALK
11 ewing sarcoma 29.9 TNFRSF8 STAT3 ALK
12 lymphoproliferative syndrome 29.9 TNFRSF8 STAT3 ALK
13 alk-negative anaplastic large cell lymphoma 29.9 STAT3 BCL2L1 ALK
14 lymphoma, non-hodgkin, familial 29.8 TNFRSF8 STAT3 NPM1 BCL2L1 ALK
15 neuroblastoma 29.7 STAT3 NPM1 BCL2L1 ALK
16 myeloid leukemia 29.7 STAT3 NPM1 BCL2L1
17 lung cancer susceptibility 3 29.6 STAT3 BCL2L1 ALK
18 t-cell lymphoblastic leukemia/lymphoma 29.6 TNFRSF8 STAT3 BCL2L1
19 adenocarcinoma 29.6 STAT3 BCL2L1 ALK
20 b-cell lymphoma 29.3 TNFRSF8 STAT3 NPM1 BCL2L1 ALK
21 hemophagocytic lymphohistiocytosis 10.5
22 yemenite deaf-blind hypopigmentation syndrome 10.4
23 inflammatory breast carcinoma 10.4
24 back pain 10.4
25 primary bone lymphoma 10.4
26 spindle cell sarcoma 10.3
27 leukemia, chronic lymphocytic 10.2
28 prostate cancer 10.2
29 meningioma, familial 10.2
30 mycobacterium tuberculosis 1 10.2
31 leukemia, chronic myeloid 10.2
32 graft-versus-host disease 10.2
33 mantle cell lymphoma 10.2
34 intracranial meningioma 10.2
35 angioimmunoblastic t-cell lymphoma 10.2
36 osteomyelitis 10.2
37 respiratory failure 10.2
38 hemopericardium 10.2
39 nephrotic syndrome 10.2
40 toxic shock syndrome 10.2
41 lymphadenitis 10.2
42 myeloproliferative neoplasm 10.2
43 acute kidney failure 10.2
44 liposarcoma 10.2
45 lactic acidosis 10.2
46 secretory meningioma 10.2
47 lymphoplasmacyte-rich meningioma 10.2
48 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.2
49 neurofibromatosis 10.2
50 leukemia, t-cell, chronic 10.2

Graphical network of the top 20 diseases related to Alk-Positive Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Positive Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.55 DDB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-109 9.55 DDB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.55 JAK3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-111 9.55 DDB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.55 TNFRSF8
6 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.55 DDB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.55 JAK3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-18 9.55 TNFRSF8
9 Increased shRNA abundance (Z-score > 2) GR00366-A-20 9.55 JAK3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.55 DDB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.55 TNFRSF8
12 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.55 TNFRSF8
13 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.55 JAK3 TNFRSF8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.55 DDB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.55 JAK3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.55 JAK3

MGI Mouse Phenotypes related to Alk-Positive Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.63 ALK BCL2L1 DDB1 JAK3 STAT3 TNFRSF8
2 neoplasm MP:0002006 9.26 ALK BCL2L1 NPM1 STAT3
3 vision/eye MP:0005391 9.02 ALK DDB1 JAK3 NPM1 STAT3

Drugs & Therapeutics for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs for Alk-Positive Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 1, Phase 2 154-93-8 2578
2
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
3
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
4
nivolumab Approved Phase 2 946414-94-4
5
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
6
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
7
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
8
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
9
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
10
Etoposide Approved Phase 2 33419-42-0 36462
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
13
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
14
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
15
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
16
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
18
Ichthammol Approved Phase 2 8029-68-3
19
Ifosfamide Approved Phase 2 3778-73-2 3690
20
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
23
Cortisone Experimental Phase 1, Phase 2 53-06-5 222786
24 Nitrogen Mustard Compounds Phase 1, Phase 2
25 Angiogenesis Inhibitors Phase 1, Phase 2
26 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
27 Protein Kinase Inhibitors Phase 2
28 Tubulin Modulators Phase 2
29 Antirheumatic Agents Phase 2
30 Alkylating Agents Phase 2
31 Etoposide phosphate Phase 2
32 Immunosuppressive Agents Phase 2
33 Antimitotic Agents Phase 2
34 Anti-Infective Agents Phase 2
35 Antiviral Agents Phase 2
36 Dermatologic Agents Phase 2
37 Antimetabolites Phase 2
38 Podophyllotoxin Phase 2 518-28-5
39 Keratolytic Agents Phase 2
40
Liposomal doxorubicin Phase 2 31703
41 Hormones Phase 2
42 Antibiotics, Antitubercular Phase 2
43 Anti-Bacterial Agents Phase 2
44 Hormone Antagonists Phase 2
45 glucocorticoids Phase 2
46 Antineoplastic Agents, Hormonal Phase 2
47 Anti-Inflammatory Agents Phase 2
48
Isophosphamide mustard Phase 2 100427
49 Folic Acid Antagonists Phase 2
50
protease inhibitors Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Unknown status NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
2 Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma Completed NCT01035463 Phase 1, Phase 2 Carmustine;Cytarabine;Etoposide;Lenalidomide;Melphalan
3 A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3) Recruiting NCT03505554 Phase 2 Lorlatinib
4 Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) Recruiting NCT03703050 Phase 2 Nivolumab cohort 1;Nivolumab cohort 2
5 A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
6 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Active, not recruiting NCT02419287 Phase 2 crizotinib
7 A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy Active, not recruiting NCT02462538 Phase 1, Phase 2 Brentuximab vedotin;Imatinib
8 A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) Suspended NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
9 Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL Terminated NCT02572453 Phase 2 Onalespib
10 A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma Withdrawn NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
11 A Phase II Study of Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Withdrawn NCT03719898 Phase 2 Brigatinib
12 An Open-Label, Phase 1/2 Dose Escalation and Expansion Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Brigatinib as Monotherapy in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors Withdrawn NCT04260009 Phase 1, Phase 2 Brigatinib;Brigatinib AAF
13 Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL) Completed NCT01366170
14 Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma Recruiting NCT03603847
15 A Prospective Multicenters Clinical Cohort Study of the Efficacy and Safety of Stratified Risk Factors for Treatment of Chinese Children With Systemic ALK-positive Anaplastic Large Cell Lymphoma Recruiting NCT03971305

Search NIH Clinical Center for Alk-Positive Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Positive Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Positive Anaplastic Large Cell Lymphoma:

40
Breast, Bone, Myeloid, Bone Marrow, Skeletal Muscle, Small Intestine, Pancreas

Publications for Alk-Positive Anaplastic Large Cell Lymphoma

Articles related to Alk-Positive Anaplastic Large Cell Lymphoma:

(show top 50) (show all 247)
# Title Authors PMID Year
1
Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL). 61
32895754 2021
2
Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series. 61
33661174 2021
3
Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). 61
33155495 2021
4
Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease? 61
33687135 2021
5
Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR. 61
33246076 2021
6
Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers? 61
33562105 2021
7
Diagnostic Challenge of Sarcomatoid Variant of ALK-Positive Anaplastic Large Cell Lymphoma: Case Report and Updated Systematic Literature Review. 61
33427000 2021
8
[Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation]. 61
33551421 2021
9
Lymphoma subtypes in India: a tertiary care center review. 61
33481141 2021
10
Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent. 61
33430343 2021
11
Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL. 61
33402581 2021
12
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. 61
32808682 2020
13
Systemic ALK-positive anaplastic large cell lymphoma with bilateral optic neurolymphomatosis resulting in permanent blindness. 61
33363793 2020
14
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. 61
33010107 2020
15
Anaplastic Large Cell Lymphoma Masquerading as Submandibular Sialolithiasis. 61
33415042 2020
16
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth. 61
31956933 2020
17
Diagnosis of the leukemic phase of ALK-positive anaplastic large cell lymphoma by immunohistochemistry on cell block prepared from peripheral blood buffy coat. 61
33154326 2020
18
Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma. 61
31649129 2020
19
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma. 61
31177400 2020
20
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. 61
31804622 2020
21
Anaplastic Large Cell Lymphoma Involving 7 Different Organs in a Pediatric Patient Demonstrated by FDG PET/CT. 61
31977482 2020
22
Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition. 61
32132036 2020
23
Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma. 61
32457846 2020
24
Primary central nervous system ALK-positive anaplastic large cell lymphoma with CD56 abnormally expression in a Chinese child: Challenge in diagnostic practice. 61
32664812 2020
25
Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report. 61
33134180 2020
26
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. 61
31004022 2019
27
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin. 61
31893088 2019
28
Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. 61
31072226 2019
29
ALK-positive anaplastic large cell lymphoma of the thoracic spine occurring in pregnancy: A case report. 61
31616703 2019
30
ALK-positive anaplastic large cell lymphoma presenting multiple lymphomatous polyposis: A case report and literature review. 61
31423437 2019
31
ALK-positive anaplastic large cell lymphoma with a monomorphic small-cell pattern masquerading as inflammatory gastric lesions. 61
31427559 2019
32
Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Young Adult-Report of a Rare Case. 61
30994389 2019
33
NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma. 61
31390744 2019
34
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. 61
30679328 2019
35
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening. 61
31151983 2019
36
[Clinical Features and Prognostic Factors of 18 Children with Anaplastic Large Cell Lymphoma]. 61
31204936 2019
37
Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib. 61
30819904 2019
38
Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. 61
30742941 2019
39
Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma. 61
31052302 2019
40
CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma. 61
30408331 2019
41
NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma. 61
31428523 2019
42
The prognostic role of 18F-FDG PET/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma. 61
31737117 2019
43
A case report of atypical Spitz tumor harboring a novel MLPH-ALK gene fusion with discordant ALK immunohistochemistry results. 61
29514107 2018
44
Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma. 61
30077013 2018
45
[Clinical outcomes of peripheral blood stem cell transplantation for aggressive peripheral T-cell lymphoma]. 61
30369182 2018
46
ALK-positive anaplastic large-cell lymphoma with primary bone involvement: A rare case and review of the literature. 61
30173234 2018
47
A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial. 61
30140094 2018
48
Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes. 61
29697184 2018
49
Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation: A case report. 61
29952979 2018
50
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. 61
29512859 2018

Variations for Alk-Positive Anaplastic Large Cell Lymphoma

Expression for Alk-Positive Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Positive Anaplastic Large Cell Lymphoma.

Pathways for Alk-Positive Anaplastic Large Cell Lymphoma

Pathways related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 TNFRSF8 STAT3 JAK3 BCL2L1 ALK
2
Show member pathways
13.28 TNFRSF8 STAT3 JAK3 BCL2L1 ALK
3
Show member pathways
13.03 TNFRSF8 STAT3 JAK3 BCL2L1
4
Show member pathways
12.81 STAT3 JAK3 DDB1 BCL2L1
5
Show member pathways
12.4 STAT3 NPM1 BCL2L1
6
Show member pathways
12.36 STAT3 JAK3 ALK
7 12.28 STAT3 JAK3 BCL2L1 ALK
8
Show member pathways
12.26 STAT3 JAK3 BCL2L1
9 12.21 TNFRSF8 STAT3 JAK3
10
Show member pathways
12.01 STAT3 JAK3 BCL2L1
11
Show member pathways
11.96 STAT3 JAK3 BCL2L1
12 11.81 STAT3 JAK3 DDB1
13
Show member pathways
11.47 TNFRSF8 BCL2L1
14 11.46 STAT3 JAK3
15
Show member pathways
11.42 JAK3 BCL2L1
16 11.39 STAT3 JAK3 BCL2L1
17
Show member pathways
11.31 STAT3 JAK3
18 11.27 STAT3 BCL2L1
19
Show member pathways
11.14 STAT3 BCL2L1
20 11.03 STAT3 JAK3
21 11 STAT3 BCL2L1
22 10.83 STAT3 JAK3
23
Show member pathways
10.78 STAT3 JAK3 BCL2L1
24 10.5 STAT3 NPM1 JAK3 ALK

GO Terms for Alk-Positive Anaplastic Large Cell Lymphoma

Biological processes related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.7 TNFRSF8 STAT3 NPM1
2 cytokine-mediated signaling pathway GO:0019221 9.65 STAT3 JAK3 BCL2L1
3 regulation of apoptotic process GO:0042981 9.61 JAK3 BCL2L1 ALK
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.54 STAT3 NPM1 ALK
5 response to cytokine GO:0034097 9.51 STAT3 BCL2L1
6 negative regulation of autophagy GO:0010507 9.49 STAT3 BCL2L1
7 energy homeostasis GO:0097009 9.46 STAT3 ALK
8 interleukin-7-mediated signaling pathway GO:0038111 9.4 STAT3 JAK3
9 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.32 STAT3 JAK3
10 interleukin-15-mediated signaling pathway GO:0035723 9.26 STAT3 JAK3
11 regulation of mitochondrial membrane permeability GO:0046902 9.16 STAT3 BCL2L1
12 interleukin-9-mediated signaling pathway GO:0038113 8.96 STAT3 JAK3
13 interleukin-21-mediated signaling pathway GO:0038114 8.62 STAT3 JAK3

Sources for Alk-Positive Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....